June 5, 2008 - Tranzyme Pharma, a leading biopharmaceutical company that discovers and develops small molecule drugs for the treatment of gastrointestinal and metabolic diseases, announced that Dr. Niels Ejskjaer, MD, PhD of Aarhus University Hospital, Denmark, will present Phase IIa trial results of Tranzyme’s first-in-class ghrelin agonist TZP-101 at the American Diabetes Association, 68th Annual Meeting to be held in San Francisco, CA, June 6-10, 2008.Using scintigraphy and a standardized radiolabeled meal, this double blind, randomized, two-way crossover study assessed the effects of TZP-101 on gastric emptying in 10 patients with long standing type 1 or type 2 diabetes and severe symptomatic gastroparesis... Tranzyme Pharma's Press Release -
